2025 Annual Report of Hengrui Medicine: Net revenue and net profit hit new highs again, innovation-driven growth

On March 25th, Hengrui Pharmaceuticals released its annual report for the year 2025. During the reporting period, the company achieved record-high revenue and net profit. The annual operating income reached 31.629 billion yuan, a year-on-year increase of 13.02%; the net profit attributable to shareholders of the listed company was 7.711 billion yuan, a year-on-year increase of 21.69%; the sales revenue of innovative drugs was 16.342 billion yuan, a year-on-year increase of 26.09%, accounting for 58.34% of the total drug sales revenue; the licensing revenue from external sources was 3.392 billion yuan, a year-on-year increase of 25.62%.